HKUMed & HKUST research team (IMAGE)
Caption
A joint research team from the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and The Hong Kong University of Science and Technology (HKUST) have demonstrated that ZCB11, a broadly neutralising antibody derived from a local mRNA-vaccinee against the spreading Omicron variants of SARS-CoV-2, displays potent antiviral activities against all variants of concern (VOCs), including the dominantly spreading Omicron BA.1, BA1.1 and BA.2. The research team members include (from right): Professor Chen Zhiwei, Director of AIDS Institute of the University of Hong Kong and Professor of the Department of Microbiology, School of Clinical Medicine, HKUMed, and Professor Dang Shangyu, Assistant Professor of Division of Life Science, the Hong Kong University of Science and Technology.
Credit
The University of Hong Kong
Usage Restrictions
N/A
License
Original content